Gyre Therapeutics, Inc. Shareholders' Equity
Gyre Therapeutics, Inc. (GYRE) had Shareholders' Equity of $107.93 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent $107.93M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $101.31M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $62.50M; Stockholders' Equity Attributable to Parent as first filed $106.03M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $101.92M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $107.93M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $101.31M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $62.50M 10-Q · filed 2026-08-07 | $106.03M 10-K · filed 2026-03-13 |
| 2025-09-30 | $101.92M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $92.03M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $68.12M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $63.32M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $63.18M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $60.35M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $56.64M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$15.83M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $3.52M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | -$28.31M 10-Q · filed 2023-10-26 | |
| 2023-03-31 | -$25.95M 10-Q · filed 2023-10-26 | |
| 2022-12-31 | $42.52M 10-K · filed 2024-03-27 | -$21.69M 10-K · filed 2023-03-30 |
| 2022-09-30 | $29.38M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $79.06M 10-Q · filed 2023-10-26 | |
| 2022-03-31 | $27.08M 10-Q · filed 2023-10-26 | |
| 2021-12-31 | $41.09M 10-Q · filed 2023-10-26 | |
| 2021-09-30 | $60.74M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $85.16M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $104.09M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $76.07M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $94.06M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $108.96M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $97.52M 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $68.34M 10-K · filed 2022-03-31 | |
| 2019-09-30 | $81.27M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $93.11M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $105.81M 10-Q · filed 2020-11-05 | $105.81M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $119.94M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $129.95M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $136.96M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $142.85M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $30.77M 10-K · filed 2020-02-20 | |
| 2017-09-30 | $24.88M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $30.35M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $13.84M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $16.07M 10-K · filed 2019-03-08 | |
| 2016-09-30 | $19.60M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $23.48M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $27.99M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $31.43M 10-K · filed 2018-03-19 | |
| 2015-09-30 | $36.21M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$113.84M 8-K/A · filed 2015-10-23 | $99.53M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $103.23M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | -$109.35M 10-K · filed 2017-03-08 | $109.08M 10-K · filed 2015-03-16 |
| 2014-09-30 | $112.91M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $117.02M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $124.10M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | -$103.01M 10-K · filed 2016-03-09 | $134.61M 10-K · filed 2014-03-14 |
| 2013-09-30 | $146.73M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $158.18M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $169.46M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | -$93.34M 10-K · filed 2016-03-09 | $175.91M 10-K · filed 2013-03-15 |
| 2012-09-30 | $190.57M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $196.36M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $178.70M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $174.29M 10-K · filed 2015-03-16 | |
| 2011-09-30 | $182.01M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $189.10M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $91.85M 10-K · filed 2014-03-14 | |
| 2009-12-31 | $68.99M 10-K · filed 2013-03-15 | |
| 2008-12-31 | $57.37M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |